BRD4 and malignant peripheral nerve sheath tumor: This results in MPNST sensitivity to BRD4 inhibitor JQ1.14,88,89 Additionally, utilizing EZH2 inhibitors, such as tazemetostat could be considered in combination therapies targeting the PRC2 complex.